Presentation is loading. Please wait.

Presentation is loading. Please wait.

DIA Bayesian Scientific Working Group 2018 Annual Meeting

Published byKathlyn Knight Modified over 6 years ago

Similar presentations

Presentation on theme: "DIA Bayesian Scientific Working Group 2018 Annual Meeting"— Presentation transcript:

1 DIA Bayesian Scientific Working Group 2018 Annual Meeting
Washington, DC

2 Agenda pm Introduction and overview of BSWG Presenter: Dr. Fanni Natanegara pm ADSWG collaboration Presenter: Dr. Bob Beckman 6.00 – 6.30pm Technical discussion Lead: Dr. Cristiana Mayer Topic: Best practices on innovative trial design simulations 6.30 – 7.00pm Lead: Dr. Satrajit Roychoudhury Topic: Historical data in confirmatory setting 7.00 – 7.30 pm Floor Discussion Dinner to follow District Kitchen 2606 Connecticut Ave NW, Washington, DC 20008 Planning Committee Freda Cooner (Sanofi) Mathangi Gopalakrishnan (University of Maryland) Samiran Ghosh (Wayne University) Amy Lalonde (Eli Lilly) Fanni Natanegara (Eli Lilly) Karen Price (Eli Lilly) Amy Xia (Amgen) Sponsors

3 Who are we? Group of representatives from Regulatory, Academia, and Industry, engaging in scientific discussion/collaboration Vision Ensure that Bayesian methods are well-understood, accepted, and broadly utilized for design, analysis, and interpretation to improve patient outcomes throughout the medical product development process and to improve decision making.

4 Lead Team Chair: Fanni Natanegara (Eli Lilly)
Vice-Chair: Amy Xia (Amgen) Past Chair: Karen Price (Eli Lilly) Secretaries: Qi Tang (Sanofi), Pritibha Singh (Novartis) Publication Chairs: Freda Cooner (Sanofi), Samiran Ghosh (Wayne State Univ) Webmaster: Frank Liu (Merck) Chairs of each Subteam (next page)

5 Subteams and Chairs For more information: www.bayesianscientific.org
Safety: Melvin Munsaka Karen Price Amy Xia Education: Fanni Natanegara Medical outreach*: Jennifer Clark , Ross Bray Deborah Wenkert Best practice*: Cory Heilmann Survey on use of AD in medical device*: Amy LaLonde and Mitch Thomann Historical data/prior specification: John Zhong and Satrajit Roychoudhury Non-inferiority: Mani Lakshminarayanan Standards reporting/tools: Mani Lakshminarayanan; Melvin Munsaka Missing Data: Frank Liu Jiajun Liu Benefit/Risk: Carl DiCasoli Program-wide decision making: Bin Yao and Karen Price Joint with Pediatric community and ADSWG*: Meg Gamalo MAPP (Medicine Adaptive Pathways to Patients)*: Larry Gould Zoran Antonevic Bob Campbell Joint Modeling: Larry Gould For more information:

6 Operations Annual face to face meetings Quarterly lead team meetings
Quarterly group meetings Establish charter for each subteam Subteam meetings at the discretion of each chair/co-chairs Regular meetings between BSWG and ADSWG officers

7 Subteam Updates (1) Safety: 1) manuscript in progress- extend Bayesian hierarchical models for safety detection 2) manuscript in progress- Bayesian meta-analysis in safety data Education: continue to build case example repository on the DIA website AD survey in medical device: finalized survey to distribute by end of 2018 Best practice: book chapter in progress- provides recommendations on the level of detail to include in protocols and analysis plan for Bayesian simulation as well as simulation plan and simulation report to support study design. Historical data/prior specification: book chapter in progress- considerations of integrating historical information into confirmatory trials from a practical perspective

8 Subteam Updates (2) Standards reporting/tools: 1) book chapter in progress- Reporting of Bayesian Analyses in Clinical Research: Some Recommendations 2) book chapter in progress-Software Tools for Bayesian Analysis Missing Data: 1) book chapter in progress- incorporate historical control data in clinical trials 2)review and understand new framework as defined in ICH E9 (R1) addendum Benefit/Risk:1) manuscript completed 2) book chapter completed Pediatric community: 1) book chapter in progress 2) continue research on innovative and efficient trial designs on pediatric population and extrapolation methods Medical outreach: coordinate and provide adaptive and Bayesian educational support to medical colleagues 1) Focus group questionnaire 2) industry wide survey 3) create educational materials and facilitate adaptive & Bayesian trainings for clinicians Potential new subteam will form on the topic of Real World Evidence (Mani Lakshminarayanan)

9 External landscape 21st Century Cures Act: signed into law on Dec 13, 2016 Accelerate medical product development and bring new innovations and advances to patients who need them faster and more efficiently Section III, Subtitle C: Modern Trial Design and Evidence Development, Section 3021: Novel clinical trial designs Prescription Drug User Fee Act (PDUFA) VI: provides FDA with necessary resources to maintain predictable and efficient review process Develop expertise, staff capacity, series of workshops, guidances, pilot programs Advancing Model-Informed Drug Development (MIDD): facilitate the development and application of exposure-based, biological, and statistical models derived from preclinical and clinical data sources. April 16, 2018: Federal Register for MIDD pilot program opened. Advancing Complex Innovative Designs (CID): Facilitate the advancement and use of complex adaptive, Bayesian, and other novel clinical trial designs. Aug 30, 2018: Federal Register for CID pilot program opened. Actively engaging in BIO and PhRMA working groups Collaborative dialogue with FDA to ensure success of the CID and MIDD initiatives and pilot programs Proactively discuss industry questions on the initiatives and pilot programs Identify opportunities for scientific contribution to maximize learning and value from the initiatives and pilot programs

10 Opportunities Continue progress and seek opportunities with each subteam Need steward(s) for case examples repository and liaise between DIA and contributors. New case examples are welcome! Need organizer(s) to set topics and reach out to speakers for the monthly Bayesian KOL lecture series Continue collaboration with DIA ADSWG Joint conference in 2019 Subteams with joint membership: Medical outreach, expedited approvals, best practices document, survey for the use of adaptive design in medical device, pediatric, website Organize and contribute to conference/workshop sessions, short courses, manuscripts, etc to facilitate effort in public learning

Download ppt "DIA Bayesian Scientific Working Group 2018 Annual Meeting"

Similar presentations

6th European Patients’ Rights Day The EMA Geriatric Medicines Strategy and the empowered aging patient Francesca Cerreta EMA (European Medicines Agency)

6th European Patients’ Rights Day The EMA Geriatric Medicines Strategy and the empowered aging patient Francesca Cerreta EMA (European Medicines Agency)
AIAA Task Force on Earth Observations 2 October 2009 AIAA HQ Reston VA.

AIAA Task Force on Earth Observations 2 October 2009 AIAA HQ Reston VA.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDAs website for reference purposes only. It.

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDAs website for reference purposes only. It.
Felicia Barnett Ronald B. Landy USEPA Office of Research and Development Office of Science Policy Regional Science Program.

Felicia Barnett Ronald B. Landy USEPA Office of Research and Development Office of Science Policy Regional Science Program.
NCI Review of the Clinical Trials Process 6 th Annual National Forum on Biomedical Imaging in Oncology James H. Doroshow M.D. April 7, 2005 Bethesda, Maryland.

NCI Review of the Clinical Trials Process 6 th Annual National Forum on Biomedical Imaging in Oncology James H. Doroshow M.D. April 7, 2005 Bethesda, Maryland.
Current Plan for Critical Path Initiative Janet Woodcock, M.D. Acting Deputy Commissioner For Operations November 5, 2004.

Current Plan for Critical Path Initiative Janet Woodcock, M.D. Acting Deputy Commissioner For Operations November 5, 2004.
Research in the Office of Vaccines Research and Review: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation and Research.

Research in the Office of Vaccines Research and Review: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation and Research.
Research in the Office of Cellular, Tissue and Gene Therapies: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation.

Research in the Office of Cellular, Tissue and Gene Therapies: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation.
ICH Quality Topics Update

ICH Quality Topics Update
PhUSE Computational Science Working Groups Solutions Through Collaboration.

PhUSE Computational Science Working Groups Solutions Through Collaboration.
Presented by Eliot Christian, USGS Accessibility, usability, and preservation of government information (Section 207 of the E-Government Act) April 28,

Presented by Eliot Christian, USGS Accessibility, usability, and preservation of government information (Section 207 of the E-Government Act) April 28,
Pilot Grant Program EGAD Study OCCUPATIONAL & ENVIRONMENTAL HEALTH.

Pilot Grant Program EGAD Study OCCUPATIONAL & ENVIRONMENTAL HEALTH.
Center for Biologics Evaluation and Research, FDA Site Visit Introduction Kathryn M. Carbone, M.D. Associate Director for Research.

Center for Biologics Evaluation and Research, FDA Site Visit Introduction Kathryn M. Carbone, M.D. Associate Director for Research.
EHealth Initiative Business and Clinical Motivator Work Group January 21, 2016 1:00 p.m. EDT.

EHealth Initiative Business and Clinical Motivator Work Group January 21, :00 p.m. EDT.
FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology July 22-23, 2008 Introduction and Update Helen N. Winkle Director, Office of.

FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology July 22-23, 2008 Introduction and Update Helen N. Winkle Director, Office of.
Overcoming challenges in pediatric oncology product development: Regulatory oversight of multi-national clinical studies Ursula Kern, Advisory Committees.

Overcoming challenges in pediatric oncology product development: Regulatory oversight of multi-national clinical studies Ursula Kern, Advisory Committees.
VICH Training Strategy Steven D. Vaughn, DVM Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine U.S. Food and Drug Administration.

VICH Training Strategy Steven D. Vaughn, DVM Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine U.S. Food and Drug Administration.
Office of the Vice President & General Counsel 300 North Ingalls Building, Suite 3B04 (734) 764-2178 Right to Try: Evolution of State and National Policy.

Office of the Vice President & General Counsel 300 North Ingalls Building, Suite 3B04 (734) Right to Try: Evolution of State and National Policy.
Patient Engagement in Drug Development: Experiences, Good Practices and Lessons Learned Lana Skirboll VP Science Policy Sanofi October 28, 2016, National.

Patient Engagement in Drug Development: Experiences, Good Practices and Lessons Learned Lana Skirboll VP Science Policy Sanofi October 28, 2016, National.
Impact of Adaptive Design on Modern Drug Development.

Impact of Adaptive Design on Modern Drug Development.

Similar presentations

Ads by Google